利妥昔单抗治疗弥漫大B细胞淋巴瘤的临床观察

目的观察利妥昔单抗治疗弥漫性大B细胞淋巴瘤(DLBCL)的疗效和不良反应。方法采用R-CHOP-21方案对40例DLBCL患者进行联合化疗。结果治疗2周期后近期疗效评价,CR15例(37.5%),PR14例(35%),有效率(RR)为72.5%。在不良反应中,Ⅳ度皮疹和心律失常各1例。结论利妥昔单抗近期疗效好;在不良反应中,Ⅳ度皮疹和心律失常必须及时发现和治疗。...

Full description

Saved in:
Bibliographic Details
Published in:肿瘤防治研究 Vol. 38; no. 8; pp. 947 - 949
Main Author: 王志军 吴月兵
Format: Journal Article
Language:Chinese
Published: 2011
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:目的观察利妥昔单抗治疗弥漫性大B细胞淋巴瘤(DLBCL)的疗效和不良反应。方法采用R-CHOP-21方案对40例DLBCL患者进行联合化疗。结果治疗2周期后近期疗效评价,CR15例(37.5%),PR14例(35%),有效率(RR)为72.5%。在不良反应中,Ⅳ度皮疹和心律失常各1例。结论利妥昔单抗近期疗效好;在不良反应中,Ⅳ度皮疹和心律失常必须及时发现和治疗。
Bibliography:42-1241/R
WANG Zhi-jun,WU Yue-bing Department of Medical Oncology,Hubei Cancer Hospital,Wuhan 430079,China
Rituximab; Diffuse large B-cell lymphoma; Adverse drug reaction; Skin rash
Objective To observe the curative effect and drug adverse reaction of rituximab in treatment for diffuse large B-cell lymphoma(DLBCL).Methods R-CHOP-21 regimen was employed to 40 patients with DLBCL.Results The curative effects of the short-term were 15(37.5%) cases of complete response(CR),14(35%) cases of partial response(PR) and response rate(RR) was 72.5%. In drug adverse reactions,skin rash or cardiac rhythm of degree Ⅳ was 1 case respectively.Conclusion The rituximab showed strongly short-term effect with moderate adverse reaction degree Ⅳ of skin toxicity and cardiac rhythm had to be found early and treated immediately.
ISSN:1000-8578